Linatine | 10139-06-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Linatine
• 英文别名: (2R)-1-[[(4S)-4-amino-4-carboxybutanoyl]amino]pyrrolidine-2-carboxylic acid
• CAS: 10139-06-7
• 化学式: C₁₀H₁₇N₃O₅
• 分子量: 259.26
• InChiKey: KWWHDNLMGLRNRN-NKWVEPMBSA-N

物化性质

• 比旋光度：
  D25 +46.4° (c = 2.8 in water)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -5.1
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  133
• 氢给体数：
  4
• 氢受体数：
  7

安全信息

• 海关编码：
  2933990090

文献信息

• [EN] AMINE SALT OF CARBOSTYRIL DERIVATIVE<br/>[FR] SEL AMINE D'UN DERIVE DE CARBOSTYRILE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2005070892A1

  公开（公告）日：2005-08-04

  The invention provides an amine salt of a carbostyril derivative formed from a carbostyril derivative represented by the formula (1) [wherein R is a halogen atom; the substituted position of the side chain is 3- or 4-position in the carbostyril skeleton; and the bonding between 3- and 4-positions of the carbostyril skeleton is a single bond or a double bond] and an amine; and the invention is useful as drugs for treating various diseases, especially as aqueous formulations due to the superior water solubility and the superior pharmacologic effects.

  该发明提供了一种氨盐，该氨盐由一种由化学式（1）表示的卡波司替衍生物形成，其中R是卤素原子；侧链的取代位置在卡波司替骨架的3-或4-位置；卡波司替骨架的3-和4-位置之间的键合是单键或双键，并且与氨基；该发明可用作治疗各种疾病的药物，特别是由于其优越的水溶性和卓越的药理效果而作为水溶性制剂。
• Reagent and process for protecting active groups
  申请人：——

  公开号：US20030225262A1

  公开（公告）日：2003-12-04

  Silylating reagents having a group other than a divalent oxygen separating two silyl groups provide regioselective protection of reactive groups under robust conditions, such as basic conditions used in alkylation, acylation and deoxygenation. In particular, silylating reagents having a group other than oxygen separating two silyl groups are useful for protecting two hydroxy groups of a ribonucleic or deoxyribonucleic acid. Alkylation of a 2′-hydroxy group of a ribonucleoside protected with the inventive silylating agents in the presence of an excess of a mild hindered base such as sodium HMDS may be carried out without protecting the exocyclic amine and oxo functionalities of nucleobases.

  具有除了双价氧以外的其他基团的硅基化试剂，在强韧条件下提供对反应基团的区域选择性保护，例如烷基化、酰化和脱氧等碱性条件。特别是，具有除氧以外的基团分隔两个硅基团的硅基化试剂对于保护核糖核酸或脱氧核糖核酸的两个羟基是有用的。在存在过量轻微阻碍碱（如钠HMDS）的情况下，可在创新的硅基化试剂保护的核糖核苷酸的2'-羟基上进行烷基化，而无需保护嘌呤碱基的外环胺基和羟基官能团。
• Lait de vache et produit d'alimentation d'une vache pour obtenir un tel lait
  申请人：Interagri 2001 S.A.

  公开号：EP1106078A1

  公开（公告）日：2001-06-13

  Lait de vache dont le spectre d'acides gras, déterminé par chromatographie en phase gazeuse, est changé par rapport au lait classique, ce lait étant obtenu par une alimentation de la vache comprenant l'ajout à la ration de base quotidienne, d'un aliment à base de graines de lin extrudées

  通过气相色谱法测定脂肪酸谱的牛奶，与传统牛奶相比，这种牛奶的脂肪酸谱发生了变化。
• Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomic ratios
  申请人：STEMINA BIOMARKER DISCOVERY, INC.

  公开号：US10209240B2

  公开（公告）日：2019-02-19

  This present invention provides rapid, reproducible, biomarker-based screening methods for the developmental toxicity testing of compounds. The methods are designed to identify the exposure level at which a test compound perturbs metabolism in a manner predictive of developmental toxicity. In particular, the perturbation of two metabolites, ornithine and cystine, is measured, wherein a ratio of the fold change in ornithine to the fold change in cystine of less than or equal to about 0.88 is indicative of the teratogenicity of a test compound.

  本发明为化合物的发育毒性测试提供了快速、可重复、基于生物标记的筛选方法。这些方法旨在确定试验化合物以可预测发育毒性的方式扰乱新陈代谢的暴露水平。特别是，测量鸟氨酸和胱氨酸这两种代谢物的扰动，其中鸟氨酸的折叠变化与胱氨酸的折叠变化之比小于或等于约 0.88，则表明试验化合物具有致畸性。
• Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes
  申请人：DermBiont, Inc.

  公开号：US11040077B2

  公开（公告）日：2021-06-22

  Disclosed herein are compositions and methods for using human-derived Janthinobacterium lividum. Compositions improve skin health. Methods may include applying human-derived Janthinobacterium lividum over a host or host area, such as skin or mucosa, to minimize the presence of one or more microbes, maximize therapeutic effects, and/or improve health. A method to minimize a pathogenic microbe may include applying to a surface a composition including human-derived Janthinobacterium lividum and an acceptable carrier. Compositions and methods may include a prebiotic to maximize growth and/or metabolites. Compositions and methods may include human-derived Janthinobacterium lividum metabolites, such as violacein, prodigiosin, indole-3-carboxaldehyde, and lantibiotics, and/or other Postbiotics.

  本文公开了使用源自人类的 Lividum Janthinobacterium 的组合物和方法。组合物可改善皮肤健康。方法可包括在宿主或宿主区域（如皮肤或粘膜）上施用源于人的生发的Lividum Janthinobacterium，以最大限度地减少一种或多种微生物的存在，最大限度地提高治疗效果，和/或改善健康状况。减少病原微生物的方法可包括向表面施用一种组合物，该组合物包括来源于人类的Janthinobacterium lividum和一种可接受的载体。组合物和方法可包括益生元，以最大限度地提高生长和/或代谢物。组合物和方法可包括来源于人的猪蓝细菌代谢物，如violacein、prodigiosin、吲哚-3-甲醛、兰特益生菌和/或其他后益生菌。